Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date:12/3/2009

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:


    -- our ability to comply with the NASDAQ rules for continued
       listing in order to maintain the listing of our common stock
       on NASDAQ;
    -- our ability to obtain necessary financing in the near term,
       including amounts necessary to repay the loan from Bay City Capital
       by the December 31, 2009 maturity date (or earlier if certain
       repayment acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan
       from Bay City Capital;
    -- our ability to timely recruit and enroll patients in any
       future clinical trials;
    -- our failure to obtain sufficient data from enrolled
       patients that can be used to evaluate VIA-2291, thereby
       impairing the validity or statistical significance of our clinical
       trials;
    -- our ability to successfully complete our clinical trials
       of VIA-2291 on expected timetables and the outcomes of such
       clinical trials;
    -- complexities in designing and implementing cardiometabolic
       clinical trials using surrogate endpoints in Phase 1 and Phase
       2 clinical trials which may differ from the ultimate endpoints
       required for registration of a candidate drug;
    -- the results of our clinical trials, including without
       limitation, with respect to the safety and
       efficacy of VIA-2291;
    -- if the results of the ACS and CEA studies, upon further
       review and analysis, are revised, interpreted differently by
       regulatory authorities or negated by later stage clinical
       trials;
    -- our ability to obtain necessary FDA approvals, including
       to initiate future clinical trials of  VIA-2291;
    -- our ability to successfully commercialize VIA-2291;
    -- our ability to identify potential clinical candidates from
       the family of DGAT1 compounds licensed and move them into
       preclinical development;
    -- our ability to obtain and protect our intellectual property
       related to our product candidates;
    -- our potential for future growth and the development of our
       product pipeline, including the THR beta agonist
       candidate and the other compounds licensed from Roche;
    -- our ability to obtain strategic opportunities to partner
       and collaborate with large biotechnology or pharmaceutical
       companies to further develop VIA-2291;
    -- our ability to form and maintain collaborative relationships
       to develop and commercialize our product candidates;
    -- general economic and business conditions; and
    -- the other risks described under Item 1A "Risk Factors" in
       our Annual Report on Form 10-K for the fiscal year ended
       December 31, 2008, as supplemented by the risks described under
       Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for
       the quarters ended March 31, 2009, June 30, 2009 and
       September 30, 2009, each on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

SOURCE VIA Pharmaceuticals, Inc.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... ... Building on the success of the inaugural RAADfest last year, RAADfest 2017 ... in radical life extension. RAADfest combines cutting edge science presented for a lay audience, ... making it the largest most comprehensive and inclusive super longevity event in the world. ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... results to clients throughout the biopharma and life sciences industries, continue to be ... is seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information ...
(Date:6/20/2017)... Hill, CT (PRWEB) , ... June 20, 2017 ... ... support, today announced that the CTNext board of directors has formed a Higher ... by a working group composed of institution presidents and other high-ranking representatives from ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... a well-versed leader with extensive assay development and biomarker expertise, as VP of ... a Boston CRO specializing in bio-analytical assay development and sample testing services. The ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):